TRANE-TECHNOLOGIES
20.7.2020 06:32:10 CEST | Business Wire | Press release
Thermo King® , a leader in transport temperature control solutions and a brand of Trane Technologies (NYSE: TT), today announced that its new hybrid refrigeration systems for trucks and high-loaders are being delivered to customers across Europe. The new T-Series Hybrid and UT Hybrid refrigeration systems seamlessly switch between diesel and electric mode allowing transporters to operate in inner cities, residential areas and low emission zones with the unit’s diesel engine turned off.
Greggs, UK’s leading bakery food-on-the-go retailer with over 1,800 shops nationwide and serving over six million customers a week, is one of the first customers in Europe to experience the benefits of the new hybrid refrigeration systems. Three new trucks with Thermo King’s hybrid systems will contribute to lowering the environmental impact and reducing operating costs of their truck transport operations in central London.
“Thermo King units have been our systems of choice for several years now. Their units have delivered good flexibility and work efficiency to our operations, and we could also always count on the Thermo King dealer service network to support us,” said Richard Penna, group logistics manager at Greggs. “We’re very cautious about the sustainability of our transport operations. It is paramount for us to operate in inner cities with as little noise and reduced emissions as possible. It was a natural choice to work with Thermo King and equip our trucks with these new units that can easily switch from diesel operation to electric, reduce the sound level and eliminate emissions. On top of that, we expect to benefit from the lower daily fuel consumption.”
“Thermo King Hybrid technology was designed to help transport and delivery companies future-proof their refrigerated operations and investments. With this solution they can stay ahead of regulations, control their total cost of ownership and achieve important sustainability goals,” said Colm O’Grady, product manager at Thermo King. “Thermo King was the first to offer its European customers a trailer hybrid refrigeration. Now, our truck transport customers can also benefit from this cleaner and electrified transport refrigeration to make urban distribution more flexible and sustainable.”
The new hybrid single- and multi-temperature solution for trucks feature Frigoblock alternator and inverter-drive technology. The nose-mount T-Series Hybrid and under-mount UT Hybrid refrigeration automatically switches between electric and diesel operation as required or necessary. This enables the transport companies to operate in inner cities, residential areas and low emission zones with the refrigeration unit’s diesel engine turned off.
The system is also well accepted by drivers, mainly due to the simple and smooth transition from one drive technology to the other. The driver only needs to set the vehicle when leaving the depot and the system will switch electric and diesel modes seamlessly during the working day depending on the unit’s requirements.
The T-Series Hybrid and UT Hybrid solutions are aligned with Trane Technologies’ 2030 sustainability commitments , and the commitment to reduce customers’ carbon emissions by one gigaton – equivalent to the annual emissions of Italy, France and the United Kingdom combined.
About Thermo King
Thermo King is a brand of Trane Technologies (NYSE: TT), a global climate innovator, and a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers and railway cars since 1938. For more information, visit www.europe.thermoking.com
or www.tranetechnologies.com
.
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. For more information, please visit tranetechnologies.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200719005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom